Relmada Therapeutics Stock (NASDAQ:RLMD)

Forecast Ownership Financials Chart Transcripts

Previous Close

$0.60

52W Range

$0.24 - $4.47

50D Avg

$0.59

200D Avg

$1.23

Market Cap

$20.91M

Avg Vol (3M)

$1.84M

Beta

0.66

Div Yield

-

RLMD Company Profile

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

17

IPO Date

Jun 20, 2014

Website

RLMD Performance

RLMD Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	-	$-103.70M	$-161.25M
Net Income	-	$-98.79M	$-157.04M
EBITDA	-	$4.91M	$-157.04M
Basic EPS	-	$-3.28	$-5.30
Diluted EPS	-	$-3.28	$-5.30

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q1 25May 12, 25 | 4:30 PM

Q4 24Mar 27, 25 | 4:30 PM

Q3 24Nov 10, 24 | 4:30 PM

Peer Comparison

Ticker	Company
YMAB	Y-mAbs Therapeutics, Inc.
STOK	Stoke Therapeutics, Inc.
RAPT	RAPT Therapeutics, Inc.
APLT	Applied Therapeutics, Inc.
PHAT	Phathom Pharmaceuticals, Inc.